Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.
Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, Candia AF, Coffman RL, Leung ACF, Janssen RS. Ribas A, et al. Among authors: medina t. Cancer Discov. 2018 Oct;8(10):1250-1257. doi: 10.1158/2159-8290.CD-18-0280. Epub 2018 Aug 28. Cancer Discov. 2018. PMID: 30154193 Free PMC article. Clinical Trial.
Dabrafenib in the treatment of advanced melanoma.
Medina T, Amaria MN, Jimeno A. Medina T, et al. Drugs Today (Barc). 2013 Jun;49(6):377-85. doi: 10.1358/dot.2013.49.6.1968669. Drugs Today (Barc). 2013. PMID: 23807941 Review.
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma.
Ribas A, Medina T, Kirkwood JM, Zakharia Y, Gonzalez R, Davar D, Chmielowski B, Campbell KM, Bao R, Kelley H, Morris A, Mauro D, Wooldridge JE, Luke JJ, Weiner GJ, Krieg AM, Milhem MM. Ribas A, et al. Among authors: medina t. Cancer Discov. 2021 Dec 1;11(12):2998-3007. doi: 10.1158/2159-8290.CD-21-0425. Cancer Discov. 2021. PMID: 34326162 Free PMC article. Clinical Trial.
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Hassel JC, Orloff M, Larkin J, Weber J, Furness AJS, Khushalani NI, Medina T, Egger ME, Graf Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Sarnaik A. Chesney J, et al. Among authors: medina t. J Immunother Cancer. 2022 Dec;10(12):e005755. doi: 10.1136/jitc-2022-005755. J Immunother Cancer. 2022. PMID: 36600653 Free PMC article. Clinical Trial.
Phase 2 Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1 Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.
Lee S, Hamid O, Jotte R, Zakharia Y, Medina T, Gillespie-Twardy A, Mehmi I, Chandra S, Watson G, Ward P, Chaney M, Lu H, Berndt J, O'Connor BP, Rathi K, Shaikh E, Cowey CL. Lee S, et al. Among authors: medina t. Clin Cancer Res. 2024 Dec 30. doi: 10.1158/1078-0432.CCR-24-1478. Online ahead of print. Clin Cancer Res. 2024. PMID: 39786430
PD-1 inhibitor induced alopecia areata.
Guidry J, Brown M, Medina T. Guidry J, et al. Among authors: medina t. Dermatol Online J. 2018 Dec 15;24(12):13030/qt2vj8b7cv. Dermatol Online J. 2018. PMID: 30677804 Free article.
Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma.
Tobin RP, Cogswell DT, Cates VM, Davis DM, Borgers JSW, Van Gulick RJ, Katsnelson E, Couts KL, Jordan KR, Gao D, Davila E, Medina TM, Lewis KD, Gonzalez R, McFarland RW, Robinson WA, McCarter MD. Tobin RP, et al. Among authors: medina tm. Clin Cancer Res. 2023 Apr 3;29(7):1209-1219. doi: 10.1158/1078-0432.CCR-22-2495. Clin Cancer Res. 2023. PMID: 36378549 Free PMC article.
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies.
Luke JJ, Piha-Paul SA, Medina T, Verschraegen CF, Varterasian M, Brennan AM, Riese RJ, Sokolovska A, Strauss J, Hava DL, Janku F. Luke JJ, et al. Among authors: medina t. Clin Cancer Res. 2023 Jul 5;29(13):2435-2444. doi: 10.1158/1078-0432.CCR-23-0118. Clin Cancer Res. 2023. PMID: 37227176 Free PMC article. Clinical Trial.
ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms.
Couts KL, Bemis J, Turner JA, Bagby SM, Murphy D, Christiansen J, Hintzsche JD, Le A, Pitts TM, Wells K, Applegate A, Amato C, Multani P, Chow-Maneval E, Tentler JJ, Shellman YG, Rioth MJ, Tan AC, Gonzalez R, Medina T, Doebele RC, Robinson WA. Couts KL, et al. Among authors: medina t. Mol Cancer Ther. 2018 Jan;17(1):222-231. doi: 10.1158/1535-7163.MCT-17-0472. Epub 2017 Oct 20. Mol Cancer Ther. 2018. PMID: 29054983 Free PMC article.
150 results